Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Ophthalmological Practice Datlinger, Sonnwendgasse 5, 7210, Mattersburg, Austria.
Sci Rep. 2022 Feb 10;12(1):2315. doi: 10.1038/s41598-022-05950-0.
In this retrospective study the morphological response of teleangiectatic capillaries (TCs) to focal laser treatment and the functional and morphological outcome after Indocyanine green angiography (ICGA)-guided laser therapy was evaluated. TCs in eyes with diabetic macular edema (DME) were treated with laser therapy. The immediate and subsequent reaction of the TCs lumina to direct photocoagulation was monitored with customized OCT single scans. Additionally, patients were treated with intravitreal anti-VEGF as needed. 12 eyes of 9 patients with treatment naive (6 eyes) and pretreated (6 eyes) DME were followed-up for a mean of 24 months (± 8.1SD). Best-corrected visual acuity improved from 0.25 logMar (± 0.2SD) to 0.12 (± 0.10SD; p = 0.06) at each patient's last visit. During laser treatment a darkening of the TCs lumina was achieved in 91.3% of lesions. All these lesions fully resolved, whereas TCs, which showed no darkening of their lumen in OCT persisted and required re-treatment with laser. Additional anti-VEGF injections were indicated in only one eye (8.3%). The darkening of the TCs lumina visible in OCT might provide an image-biomarker that indicates successful coagulation of aneurysmatic lesions. Consequently, a significant functional and morphological improvement with need for anti-VEGF treatment in only one eye, was achieved.Information concerning the registration of the trial: date of registration: 11th of december, 2019. Trial registration number: 107/2019.
在这项回顾性研究中,评估了糖尿病性黄斑水肿(DME)患者的毛细血管扩张(TC)对激光局部治疗的形态反应,以及吲哚菁绿血管造影(ICGA)引导下激光治疗后的功能和形态结果。TC 采用激光治疗。使用定制的 OCT 单次扫描监测 TC 管腔对直接光凝的即时和后续反应。此外,根据需要对患者进行玻璃体内抗 VEGF 治疗。9 名患者的 12 只眼接受了治疗(6 只眼)和预处理(6 只眼)DME 的治疗,平均随访 24 个月(±8.1SD)。最佳矫正视力从 0.25 logMar(±0.2SD)提高到每位患者最后一次就诊时的 0.12(±0.10SD;p=0.06)。在激光治疗期间,91.3%的病变中 TC 管腔变暗。所有这些病变完全消退,而在 OCT 中没有发现 TC 管腔变暗的病变则持续存在,需要再次用激光治疗。仅一只眼(8.3%)需要额外的抗 VEGF 注射。OCT 中可见的 TC 管腔变暗可能提供了一种图像生物标志物,表明对动脉瘤样病变的成功凝固。因此,仅一只眼需要抗 VEGF 治疗,即可实现显著的功能和形态改善。关于试验登记的信息:登记日期:2019 年 12 月 11 日。试验登记编号:107/2019。